DAPTACEL Drug Profile

Summary for Tradename: DAPTACEL

High Confidence Patents:	1
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for DAPTACEL

Recent Clinical Trials for DAPTACEL

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Farrukh Awan	Phase 2
Pharmacyclics LLC.	Phase 2
Jennifer Woyach	Phase 2

See all DAPTACEL clinical trials

Pharmacology for DAPTACEL

Physiological Effect	Actively Acquired Immunity
Established Pharmacologic Class	Inactivated Bordetella Pertussis Vaccine Inactivated Clostridium Tetani Vaccine Inactivated Corynebacterium Diphtheriae Vaccine
Chemical Structure	Diphtheria Toxoid Pertussis Vaccine Tetanus Toxoid Vaccines, Inactivated

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for DAPTACEL Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for DAPTACEL Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Sanofi Pasteur Limited	DAPTACEL	diphtheria & tetanus toxoids & acellular pertussis vaccine adsorbed	Injection	103666		2015-05-04	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for DAPTACEL Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for DAPTACEL

Last updated: April 12, 2026

What is DAPTACEL?

DAPTACEL is a diphtheria, tetanus, acellular pertussis (DTaP) vaccine manufactured by Sanofi. Approved for active immunization against diphtheria, tetanus, and pertussis in infants, children, and adolescents, it is a key player in pediatric immunization programs globally.

What are the current global market trends for DTaP vaccines?

• The global DTaP vaccine market was valued at approximately $4.2 billion in 2022.
• It is projected to grow at a compound annual growth rate (CAGR) of 6-8% from 2023 to 2030.
• Growth drivers include rising vaccination awareness, government immunization initiatives, and expanding immunization coverage in developing countries.
• Market expansion is limited by vaccine hesitancy and access barriers in some regions.

What does the competitive landscape look like?

Manufacturer	Main Products	Market Share (2022)	Key Markets	Notes
Sanofi	DAPTACEL, Infanrix	~55%	North America, Europe, Asia-Pacific	Leading manufacturer, extensive portfolio
GlaxoSmithKline	Infanrix, Boostrix	~35%	North America, Europe, Asia	Strong global presence, booster vaccines
Other (e.g., Serum Institute, Valneva)	Various regional brands	~10%	Emerging markets	Competitive pricing, local production

This market is consolidating with Sanofi and GSK holding about 90% of the market share.

How have regulatory policies affected DAPTACEL?

• Many countries, including the U.S. and European nations, continue to recommend routine DTaP vaccination for children.
• Recent regulatory focus emphasizes vaccine safety, leading to enhanced post-marketing surveillance.
• The U.S. FDA approved DAPTACEL for children aged 6 weeks through 6 years; similar approvals exist globally.
• Gaps in immunization programs in developing regions limit global uptake, despite high demand.

Financial trends and projections

Revenue streams

• DAPTACEL's revenue accounts for approximately $300-350 million annually (2022 estimates).
• GSK's Infanrix dominates with about $500 million annually, but DAPTACEL retains a significant share due to its use in specific markets.

Market potential

• Emerging economies such as India, Nigeria, and Indonesia represent the fastest growth opportunities due to expanding immunization programs.
• Sanofi and competitors are pursuing local manufacturing agreements to lower costs and improve market penetration.

Pricing strategies

• DAPTACEL pricing ranges from $5 to $15 per dose, varying by region.
• Pricing pressures are present in price-sensitive markets, leading to increased focus on cost-effectiveness and biosimilar development.

R&D and pipeline prospects

• Sanofi is investing in next-generation pertussis vaccines with improved safety profiles and longer-lasting immunity.
• Multiple biosimilar candidates are under development, potentially impacting pricing and market share.

Key factors influencing DAPTACEL's financial trajectory

• Continued high vaccination coverage rates globally.
• Pricing and reimbursement policies in major markets.
• Regulatory approvals for expanded indications or new formulations.
• Competition from biosimilars and newer vaccines with enhanced efficacy.
• Public health initiatives aimed at reducing vaccine hesitancy.

Risks and challenges

• Vaccine hesitancy may slow adoption.
• Shifts towards combination vaccines could impact standalone DAPTACEL sales.
• Regulatory delays or safety concerns could impair market growth.
• Supply chain disruptions or manufacturing issues affect availability.

Conclusion

DAPTACEL remains a vital component of pediatric vaccination strategies. Its financial performance is supported by global immunization programs, but growth depends on regulatory approvals, competitive landscape developments, and market access in emerging economies. While competitors hold significant market share, DAPTACEL benefits from established regulatory approvals and manufacturer relationships.

Key Takeaways

• The global DTaP vaccine market is valued at over $4 billion, with steady growth driven by immunization initiatives.
• Sanofi’s DAPTACEL holds about 55% of the market, primarily in developed markets.
• Emerging economies are crucial for future growth, offering access and price challenges.
• Competition from GSK and biosimilar producers could pressure pricing and market share.
• Investment in next-generation vaccines and biosimilars may reshape the landscape over the next five years.

FAQs

1. How does DAPTACEL compare to other DTaP vaccines?
DAPTACEL offers comparable efficacy and safety to competitors like GSK’s Infanrix, with variations in formulation and regional approvals. Cost and supply chains influence market choice.

2. What is the regulatory outlook for DAPTACEL?
Regulatory agencies in major markets approve DAPTACEL for routine pediatric immunization, with expanding indications possible as new data emerges.

3. Are there biosimilar or generic versions of DAPTACEL?
No biosimilars are currently approved for DAPTACEL, but biosimilar development is ongoing for similar vaccines, which could impact pricing.

4. What are the primary growth markets for DAPTACEL?
India, Nigeria, Indonesia, and other developing nations present significant growth opportunities due to expanding immunization coverage.

5. How does public perception influence the market?
Vaccine hesitancy remains a barrier, particularly in developed countries, potentially affecting uptake and sales.

References

1. Market Research Future. (2023). Global DTaP vaccine market. Retrieved from https://www.mrfresearch.com
2. Sanofi. (2023). DAPTACEL product information. Retrieved from https://www.sanofi.com
3. GSK. (2023). Infanrix and Boostrix overview. Retrieved from https://www.gsk.com
4. World Health Organization. (2022). Immunization coverage data. Retrieved from https://www.who.int
5. U.S. Food and Drug Administration. (2022). Pediatric vaccine approval announcements. Retrieved from https://www.fda.gov